ADMA Biologics (ADMA) Stock Price

ADMA Biologics Price

NASDAQ·CLOSED
9.96USD+0.15 (+1.47 %)
Market closed

Over the last 13 years ADMA Biologics grew revenue by 60.2% annually, reaching 510.17 M USD. For ADMA Biologics, the net margin of 28.8% is up versus -88.5% a few years ago. The consensus 12-month price target for ADMA Biologics is 30.60 USD, about 207.2% above where the stock trades today. Of 9 analysts, 8 rate the stock a buy — an overall Buy consensus. The stock trades about 32% above its 52-week low.

ADMA Biologics stock price

Volume
Details

Stock Price

ⓘ

How to Read This Chart

This chart tracks the historical stock price of ADMA Biologics over time. You can switch between daily, weekly, and monthly views and select custom time ranges — from a single day to the full available history. Use the toggle to view price changes in absolute currency terms or as a percentage change relative to the starting date.

Total Return vs. Price Return

The "Total Return" toggle includes reinvested dividends on top of the pure price movement. This is critical because dividends can account for a significant portion of long-term returns. Historically, roughly 40 % of the S&P 500's total return has come from dividends. Always compare total return when evaluating a stock's real performance against a benchmark.

Intraday Price Data

When viewing a one-day time frame, the chart displays real-time intraday price movements. This is useful for observing how ADMA Biologics stock reacts to market openings, earnings releases, or breaking news throughout the trading session.

What to Look For

Look for long-term trends (sustained upward or downward movements over months and years), support and resistance levels (price zones where the stock repeatedly bounces or reverses), and volatility (how much the price fluctuates day to day). Comparing ADMA Biologics's price chart to a market index like the S&P 500 can reveal whether the stock is outperforming or underperforming the broader market.

ADMA Biologics Stock Price History
DateADMA Biologics Price
8/12/20269.96 USD
8/10/20269.81 USD
8/7/20269.90 USD
8/6/202610.06 USD
8/5/20269.22 USD
8/4/20268.93 USD
8/3/20268.74 USD
7/31/20268.46 USD
7/30/20268.67 USD
7/29/20268.71 USD
7/27/20268.47 USD
7/23/20268.37 USD
7/22/20268.38 USD
7/21/20268.59 USD
7/20/20268.75 USD
7/17/20268.71 USD
7/16/20268.81 USD
7/15/20268.68 USD
7/14/20268.87 USD
7/13/20268.95 USD
7/10/20269.08 USD
7/9/20269.27 USD
7/8/20269.20 USD
7/7/20269.21 USD
7/6/20269.02 USD
7/2/20268.95 USD
7/1/20268.61 USD
6/30/20268.37 USD
6/29/20268.36 USD
6/26/20268.75 USD
6/25/20268.72 USD
6/24/20268.70 USD
6/23/20268.69 USD
6/22/20268.43 USD
6/18/20268.43 USD
6/17/20268.56 USD
6/16/20268.59 USD
6/15/20268.47 USD
6/12/20268.32 USD
6/11/20268.23 USD
6/10/20268.61 USD
6/9/20268.12 USD
6/8/20268.06 USD
6/5/20268.06 USD
6/4/20267.97 USD
6/3/20267.63 USD
6/2/20267.54 USD
6/1/20267.79 USD
5/29/20268.13 USD
5/28/20267.98 USD
5/27/20268.07 USD
5/26/20268.19 USD
5/22/20268.23 USD
5/21/20268.55 USD
5/20/20268.68 USD
5/19/20268.63 USD
5/18/20268.38 USD
5/15/20268.27 USD
5/14/20268.50 USD
5/13/20268.50 USD
5/12/20268.41 USD
5/11/20267.88 USD
5/8/20268.17 USD
5/7/20268.47 USD
5/6/202610.08 USD
5/5/202610.25 USD
5/4/202610.31 USD
5/1/202610.52 USD
4/30/202610.25 USD
4/29/202610.60 USD
4/28/202610.90 USD
4/27/202610.93 USD
4/24/202611.26 USD
4/23/202611.08 USD
4/22/202610.95 USD
4/21/202610.78 USD
4/20/202610.88 USD
4/17/202611.01 USD
4/16/202610.74 USD
4/15/202610.65 USD
4/14/202610.49 USD
4/13/202610.38 USD
4/10/20269.70 USD
4/9/20269.94 USD
4/8/20269.83 USD
4/7/20269.26 USD
4/6/20269.28 USD
4/2/20269.19 USD
4/1/20269.11 USD
3/31/20269.01 USD
3/30/20269.15 USD
3/27/20269.25 USD
3/26/20268.29 USD
3/25/20269.63 USD
3/24/202611.33 USD
3/23/202613.59 USD
3/20/202614.32 USD
3/19/202615.02 USD
3/18/202614.87 USD
3/17/202616.15 USD
3/16/202615.84 USD
3/13/202615.15 USD
3/12/202614.99 USD
3/11/202615.67 USD
3/10/202615.83 USD
3/9/202615.81 USD
3/6/202615.39 USD
3/5/202615.70 USD
3/4/202616.54 USD
3/3/202616.38 USD
3/2/202616.58 USD
2/27/202615.57 USD
2/26/202615.18 USD
2/25/202615.68 USD
2/24/202615.52 USD
2/23/202616.29 USD
2/20/202616.10 USD
2/19/202616.32 USD
2/18/202615.99 USD
2/17/202615.95 USD
2/13/202616.09 USD
2/12/202615.59 USD
2/11/202616.28 USD
2/10/202616.28 USD
2/9/202616.37 USD
2/6/202616.43 USD
2/5/202615.94 USD
2/4/202616.49 USD
2/3/202617.52 USD
2/2/202617.50 USD
1/30/202617.30 USD
1/29/202617.01 USD
1/28/202616.33 USD
1/27/202616.58 USD
1/26/202616.96 USD
1/23/202616.73 USD
1/22/202617.40 USD
1/21/202617.36 USD
1/20/202617.59 USD
1/16/202617.31 USD
1/15/202617.50 USD
1/14/202618.28 USD
1/13/202617.70 USD
1/12/202617.93 USD
1/9/202617.95 USD
1/8/202618.07 USD
1/7/202618.82 USD
1/6/202618.34 USD
1/5/202618.03 USD
1/2/202617.88 USD
12/31/202518.24 USD
12/30/202518.36 USD
12/29/202519.11 USD
12/26/202519.28 USD
12/24/202519.54 USD
12/23/202519.49 USD
12/22/202519.88 USD
12/19/202519.58 USD
12/18/202518.81 USD
12/17/202518.83 USD
12/16/202519.17 USD
12/15/202519.73 USD
12/12/202519.78 USD
12/11/202520.38 USD
12/10/202519.98 USD
12/9/202519.80 USD
12/8/202519.39 USD
12/5/202519.85 USD
12/4/202520.11 USD
12/3/202519.72 USD
12/2/202519.25 USD
12/1/202519.38 USD
11/28/202519.18 USD
11/26/202519.14 USD
11/25/202519.21 USD
11/24/202518.32 USD
11/21/202517.18 USD
11/20/202516.36 USD
11/19/202515.95 USD
11/18/202515.69 USD
11/17/202515.42 USD
11/14/202515.56 USD
11/13/202515.70 USD
11/12/202516.46 USD
11/11/202516.03 USD
11/10/202514.71 USD
11/7/202514.52 USD
11/6/202514.03 USD
11/5/202515.37 USD
11/4/202514.63 USD
11/3/202515.37 USD
10/31/202515.48 USD
10/30/202515.27 USD
10/29/202515.53 USD
10/28/202515.57 USD
10/27/202515.60 USD
10/24/202515.18 USD
10/23/202515.25 USD
10/22/202515.16 USD
10/21/202514.72 USD
10/20/202514.69 USD
10/17/202514.36 USD
10/16/202514.56 USD
10/15/202515.09 USD
10/14/202514.95 USD
10/13/202514.55 USD
10/10/202514.54 USD
10/9/202514.74 USD
10/8/202514.62 USD
10/7/202513.99 USD
10/6/202514.07 USD
10/3/202514.66 USD
10/2/202514.53 USD
10/1/202515.05 USD
9/30/202514.66 USD
9/29/202514.70 USD
9/26/202515.61 USD
9/25/202515.32 USD
9/24/202515.66 USD
9/23/202515.98 USD
9/22/202516.03 USD
9/19/202515.91 USD
9/18/202516.16 USD
9/17/202515.56 USD
9/16/202515.69 USD
9/15/202515.30 USD
9/12/202516.11 USD
9/11/202516.11 USD
9/10/202515.76 USD
9/9/202516.39 USD
9/8/202516.42 USD
9/5/202516.87 USD
9/4/202516.91 USD
9/3/202516.90 USD
9/2/202517.20 USD
8/29/202517.26 USD
8/28/202517.38 USD
8/27/202517.25 USD
8/26/202517.10 USD
8/25/202517.01 USD
8/22/202517.80 USD
8/21/202517.10 USD
8/20/202517.30 USD
8/19/202517.44 USD
8/18/202517.63 USD
8/15/202516.99 USD
Access this data via the Eulerpool API
Get Free API Key

ADMA Biologics Revenue, EBIT, Net Income

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details
Date
Revenue
EBIT
Net Income
Jan 1, 2023
258.22 M USD
21.63 M USD
-28.24 M USD
Jan 1, 2024
426.45 M USD
138.98 M USD
197.67 M USD
Jan 1, 2025
510.17 M USD
191.44 M USD
146.93 M USD
Jan 1, 2026 (e)
535.35 M USD
-36.28 M USD
195.12 M USD
Jan 1, 2027 (e)
700.32 M USD
-42.77 M USD
240.62 M USD
Jan 1, 2028 (e)
728.06 M USD
-49.43 M USD
343.68 M USD
Jan 1, 2029 (e)
836.93 M USD
-56.82 M USD
363.27 M USD
Jan 1, 2030 (e)
952.62 M USD
-64.68 M USD
434.30 M USD

ADMA Biologics Income Statement, Balance Sheet, Cash Flow Statement

Last updated Aug 15, 2026, 4:25 AM
 
REVENUEM USD
REVENUE GROWTH%
GROSS MARGIN%
GROSS INCOMEM USD
EBITM USD
EBIT MARGIN%
NET INCOMEM USD
NET INCOME GROWTH%
SHARESB
201520162017201820192020202120222023202420252026e2027e2028e2029e2030e
7.0010.0022.0016.0029.0042.0080.00154.00258.00426.00510.00535.00700.00728.00836.00952.00
40.0042.86120.00-27.2781.2544.8390.4892.5067.5365.1219.724.9030.844.0014.8413.88
28.5740.00-27.27-156.25-34.48-45.241.2522.7334.1151.4157.2557.2557.2557.2557.2557.25
2.004.00-6.00-25.00-10.00-19.001.0035.0088.00219.00292.00306.31400.78416.82478.65545.07
-15.00-17.00-40.00-60.00-40.00-64.00-58.00-46.0021.00138.00191.00-36.00-42.00-49.00-56.00-64.00
-214.29-170.00-181.82-375.00-137.93-152.38-72.50-29.878.1432.3937.45-6.73-6.00-6.73-6.70-6.72
-17.00-19.00-43.00-65.00-48.00-75.00-71.00-65.00-28.00197.00146.00195.00240.00343.00363.00434.00
6.2511.76126.3251.16-26.1556.25-5.33-8.45-56.92-803.57-25.8933.5623.0842.925.8319.56
0.010.010.050.050.060.100.180.200.230.250.240.240.240.240.240.24
Details

Income Statement Key Figures

ⓘ

Revenue and Revenue Growth

Revenue is the starting point of every income statement — it measures the total sales ADMA Biologics generates from its core business. Revenue growth (expressed as year-over-year percentage change) is one of the most important indicators of business momentum. Sustained growth above 10 % annually is generally considered strong, while declining revenue is a serious warning sign that demands investigation.

Gross Margin

Gross margin = (Revenue − Cost of Goods Sold) ÷ Revenue. It reveals what percentage of each dollar of revenue ADMA Biologics retains after direct production costs. High gross margins (above 50 %) are typical of asset-light businesses like software and brands, while capital-intensive industries like manufacturing often operate below 30 %. Compare ADMA Biologics's gross margin to industry peers and track it over time to spot improving or deteriorating pricing power.

EBIT and EBIT Margin

EBIT measures operating profit — what remains after subtracting all operating expenses (including R&D, sales, and administrative costs) from gross profit. The EBIT margin shows this as a percentage of revenue. Because it excludes interest and taxes, EBIT allows fair comparisons between companies with different debt levels and tax jurisdictions. A rising EBIT margin indicates improving operational efficiency.

Net Income and Earnings Per Share (EPS)

Net income is the company's final profit after all expenses, interest, and taxes. Dividing net income by the number of shares outstanding gives you EPS — the single most influential metric in stock valuation. Consistent EPS growth is the primary driver of long-term stock price appreciation. Always check whether EPS growth comes from genuine profit improvement or from share buybacks reducing the share count.

Shares Outstanding

The total number of shares ADMA Biologics has issued. A declining share count (through buybacks) boosts EPS and signals management confidence. A rising share count (through stock issuance) dilutes existing shareholders. Always monitor this number alongside EPS to get the full picture of per-share value creation.

Analyst Estimates

The projected figures represent consensus estimates from professional analysts. Compare these forecasts against ADMA Biologics's historical growth rates to assess whether expectations are realistic. A company that consistently beats consensus estimates tends to see its stock price rewarded over time, while repeated misses erode investor confidence.

ADMA Biologics stock margins

The ADMA Biologics margin analysis displays the gross margin, EBIT margin, as well as the profit margin of ADMA Biologics. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for ADMA Biologics.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details
Date
Gross margin
EBIT margin
Profit margin
Jan 1, 2021
1.45 %
-72.43 %
-88.52 %
Jan 1, 2022
22.89 %
-30.26 %
-42.77 %
Jan 1, 2023
34.44 %
8.38 %
-10.94 %
Jan 1, 2024
51.48 %
32.59 %
46.35 %
Jan 1, 2025
57.39 %
37.53 %
28.80 %
Jan 1, 2026 (e)
57.39 %
-6.78 %
36.45 %
Jan 1, 2027 (e)
57.39 %
-6.11 %
34.36 %
Jan 1, 2028 (e)
57.39 %
-6.79 %
47.21 %

ADMA Biologics Stock Revenue, EBIT, Earnings per Share

The ADMA Biologics earnings per share therefore indicates how much revenue ADMA Biologics has generated per share in a given period. The earnings before interest and taxes per share shows how much of the operating profit corresponds to each share. The earnings per share indicates how much of the profit belongs to each share.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Revenue per Share
EBIT per share
Earnings per Share
Details
Date
Revenue per Share
EBIT per share
Earnings per Share
Jan 1, 2021
0.45 USD
-0.32 USD
-0.40 USD
Jan 1, 2022
0.76 USD
-0.23 USD
-0.32 USD
Jan 1, 2023
1.14 USD
0.10 USD
-0.12 USD
Jan 1, 2024
1.73 USD
0.57 USD
0.80 USD
Jan 1, 2025
2.09 USD
0.79 USD
0.60 USD
Jan 1, 2026 (e)
2.19 USD
-0.15 USD
0.80 USD
Jan 1, 2027 (e)
2.86 USD
-0.18 USD
0.98 USD
Jan 1, 2028 (e)
2.97 USD
-0.20 USD
1.40 USD

ADMA Biologics business model & stock analysis

ADMA Biologics is a leading company in the development and manufacturing of biological therapies for the treatment of serious diseases. The company was founded in 2004 and is headquartered in Ramsey, New Jersey. ADMA Biologics' business model is based on the development and manufacturing of specialized biological therapies tailored to the needs of patients with rare diseases and severe infections. It specializes in the development of plasma-based therapies to treat patients with immune deficiency and autoimmune diseases, hemophilia, and severe blood loss due to trauma or surgery. ADMA Biologics' products include intravenously administered immune globulin (IVIG) called BIVIGAM, approved for intravenous infusion in patients with primary immune deficiency or other immune disorders. CyclASol, an eye drop for patients with the eye inflammation Keratoconjunctivitis Sicca, is also a product developed by ADMA Biologics. Additionally, ADMA Biologics is currently expanding its product portfolio through the development of PDIG, a product in phase III clinical trial for the treatment of secondary immune deficiencies. The company has long-standing partnerships with other companies and organizations in the industry to combine its resources and expertise in the development and marketing of innovative therapies. ADMA Biologics also operates its own plasma collection center to ensure the supply of plasma for its therapies. In terms of its divisions, ADMA Biologics currently focuses on the USA, where the company offers its products through a dedicated sales team. Additionally, ADMA Biologics aims to expand its presence worldwide by introducing its products into new regions and markets. The company has achieved important regulatory milestones in Europe and other parts of the world, including the approval of BIVIGAM's sale in Korea and the Industrial Ministry Jubilee Memorial for BIVIGAM's introduction in Japan. ADMA Biologics' history began in 2004 when the company specialized in the development and manufacturing of plasma-based therapies for patients with rare diseases. In 2009, the company received its first FDA approval for ASCENIV, an immune globulin product for the treatment of immune deficiency disorders. In 2011, ADMA Biologics acquired a plasma collection center to expand its resources and capabilities and ensure an independent supply chain for plasma. Since then, the company has gained importance in the industry through the development and introduction of innovative products and therapies. In 2018, ADMA Biologics established a subsidiary in Germany to support the company's expansion into the European continent. In the same year, the company also obtained FDA approval in the United States for BIVIGAM, the first IVIG product manufactured from human plasma in the country. Overall, ADMA Biologics has a strong brand presence in the industry and is successfully expanding its portfolio of plasma-based therapies. The company has established strong partnerships with organizations in the industry to jointly develop and bring innovative solutions to a wide range of diseases. ADMA Biologics has a very positive future outlook and is expected to play a significant role in the field of biological therapies by continuing to develop and bring innovative therapies to the market.

ADMA Biologics SWOT Analysis

Strengths

ADMA Biologics Inc possesses a robust intellectual property portfolio, which provides a significant competitive advantage in the biologics industry. This comprehensive IP portfolio protects their innovative products and technologies, making it difficult for competitors to replicate or infringe upon their advancements.

ADMA Biologics Inc has state-of-the-art manufacturing facilities and a well-established production process. Their advanced manufacturing capabilities enable them to efficiently produce high-quality biologics, streamlining the supply chain and ensuring consistent product availability to meet market demands.

Weaknesses

ADMA Biologics Inc heavily relies on a single manufacturing facility for their production, which poses a potential vulnerability to their supply chain. Any disruption or operational issues at the facility could negatively impact their ability to meet market demand and fulfill orders in a timely manner.

Currently, ADMA Biologics Inc has a relatively limited product portfolio, focusing primarily on immune globulin products. This narrower range of offerings may limit their revenue potential and leave them more vulnerable to market fluctuations or competition in the biologics industry.

Opportunities

ADMA Biologics Inc can capitalize on the growing global biologics market by expanding their product offerings and entering new market segments. By diversifying their portfolio, they can target a broader customer base and enhance their revenue potential while taking advantage of increasing demand for biologic therapies worldwide.

Investing in research and development to develop new products and innovative therapies can open up new revenue streams for ADMA Biologics Inc. By focusing on expanding their pipeline, they can stay ahead of competitors and address unmet medical needs, positioning themselves as a leading player in the biologics market.

Threats

The biologics industry is highly competitive with numerous established players and new entrants. ADMA Biologics Inc faces the risk of increased competition, pricing pressures, and potential loss of market share if they fail to differentiate their products effectively or keep up with technological advancements and industry trends.

As a biologics company, ADMA Biologics Inc is subject to rigorous regulatory requirements and quality control standards. Any failure to comply with these regulations or maintaining proper documentation can result in regulatory penalties, product recalls, damage to reputation, and potential legal action, posing a significant threat to their operations and financial stability.

ADMA Biologics Employees

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

ADMA Biologics Employees
Details
Date
ADMA Biologics Employees
Jan 1, 2018
- Employees
Jan 1, 2019
- Employees
Jan 1, 2020
- Employees
Jan 1, 2021
- Employees
Jan 1, 2022
- Employees
Jan 1, 2023
- Employees
Jan 1, 2024
- Employees
Jan 1, 2025
- Employees

ADMA Biologics Segments

ADMA Biologics Revenue by Segment (1/2)

  • 3 Years

  • Max

Product Revenue
License Revenue
Details
Date
Product Revenue
License Revenue
Jan 1, 2016
0.00 USD
0.00 USD
Jan 1, 2017
0.00 USD
0.00 USD
Jan 1, 2018
0.00 USD
0.00 USD
Jan 1, 2019
0.00 USD
0.00 USD
Jan 1, 2020
0.00 USD
0.00 USD
Jan 1, 2021
80.80 M USD
142,834.00 USD
Jan 1, 2022
153.94 M USD
142,834.00 USD
Jan 1, 2023
0.00 USD
0.00 USD

ADMA Biologics Revenue by Segment (2/2)

  • 3 Years

  • 5 Years

  • 10 Years

  • Max

Consolidated (member)
ADMA BioManufacturing
Plasma Collection Center
Plasma Collection Centers
Corporate
Research And Development
Details
Date
Consolidated (member)
ADMA BioManufacturing
Plasma Collection Center
Plasma Collection Centers
Corporate
Research And Development
Jan 1, 2016
0.00 USD
0.00 USD
0.00 USD
10.52 M USD
142,834.00 USD
0.00 USD
Jan 1, 2017
0.00 USD
10.98 M USD
0.00 USD
11.64 M USD
142,834.00 USD
0.00 USD
Jan 1, 2018
0.00 USD
6.80 M USD
0.00 USD
10.04 M USD
142,834.00 USD
0.00 USD
Jan 1, 2019
0.00 USD
22.18 M USD
0.00 USD
7.03 M USD
142,834.00 USD
0.00 USD
Jan 1, 2020
42.22 M USD
36.67 M USD
0.00 USD
5.40 M USD
142,834.00 USD
0.00 USD
Jan 1, 2021
0.00 USD
0.00 USD
0.00 USD
0.00 USD
142,834.00 USD
0.00 USD
Jan 1, 2022
0.00 USD
0.00 USD
0.00 USD
0.00 USD
142,834.00 USD
0.00 USD
Jan 1, 2023
0.00 USD
0.00 USD
0.00 USD
0.00 USD
143,000.00 USD
0.00 USD

ADMA Biologics Revenue by Region

  • 3 Years

  • Max

United States
International
Details
Date
United States
International
Jan 1, 2021
70.63 M USD
10.32 M USD
Jan 1, 2022
146.43 M USD
7.65 M USD
Jan 1, 2023
244.88 M USD
13.33 M USD
Jan 1, 2024
410.15 M USD
16.31 M USD

ADMA Biologics Eulerpool Fair Value

Details

Fair Value Estimate

ⓘ

What Is Fair Value?

Fair value is an estimate of what a stock is truly "worth" based on its financial fundamentals, independent of the current market price. If the calculated fair value is above the current share price, the stock may be undervalued — and vice versa. This chart shows three different fair value approaches so you can cross-check them against each other.

Earnings-Based Fair Value

Calculated by multiplying the current earnings per share (EPS) by the average historical P/E ratio over a selected multi-year period. The smoothing over several years filters out temporary spikes or dips. If this fair value exceeds the market price, it suggests the stock is cheap relative to its earning power.

Example: Fair Value (Earnings) 2022 = EPS 2022 × Average P/E 2019–2021

Revenue-Based Fair Value

Derived by multiplying revenue per share by the average historical price-to-sales ratio. This method is particularly useful for companies with volatile or temporarily depressed earnings, as revenue tends to be more stable than profits. It answers: "At what price has the market historically valued each dollar of this company's sales?"

Example: Fair Value (Revenue) 2022 = Revenue per Share 2022 × Average P/S 2019–2021

Dividend-Based Fair Value

Calculated by dividing the dividend per share by the average historical dividend yield. This approach is most relevant for mature, consistently dividend-paying companies. If the resulting fair value is higher than the current price, it implies the stock offers a better yield than its historical average.

Example: Fair Value (Dividend) 2022 = Dividend per Share 2022 ÷ Average Yield 2019–2021

How to Use This Chart

When all three fair value lines converge above the current price, it strengthens the case that the stock is undervalued. When they diverge, investigate why — it may indicate a structural shift in margins, payout policy, or growth rate. The forward estimates on the right extend the analysis using projected fundamentals, helping you assess whether the current price already reflects future growth expectations.

ADMA Biologics historical P/E ratio, EBIT multiple, and P/S ratio

ADMA Biologics annual returns

Details

Annual Return

ⓘ

What This Chart Shows

This chart breaks down 's total annual return into two components: price return (gains or losses from stock price movement) and dividend return (income received from dividend payments). Together, they represent the total return an investor would have earned in each calendar year.

Price Return

Price return measures the percentage change in 's stock price from January 1st to December 31st of each year. Positive bars indicate the stock appreciated; negative bars show a decline. This is the component most investors focus on, but it tells only part of the story — especially for dividend-paying stocks.

Dividend Return

Dividend return represents the income generated from dividends paid during the year, expressed as a percentage of the starting stock price. While it may seem small in any single year (typically 1–4 % for established companies), dividends compound significantly over decades and have historically contributed roughly 40 % of total stock market returns.

What to Look For

Examine how many years showed positive vs. negative returns to gauge consistency. A stock with mostly positive years and small drawdowns suggests lower risk. Also compare 's annual returns to a benchmark index — consistently outperforming the market is a hallmark of a strong investment. Pay attention to the worst years: understanding downside risk is just as important as chasing upside potential.

ADMA Biologics shares outstanding

The number of shares of ADMA Biologics was 243.85 M in 2025. This indicates how many shares ADMA Biologics is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Number of stocks
Details
Date
Number of stocks
Jan 1, 2021
180.81 M Stocks
Jan 1, 2022
202.83 M Stocks
Jan 1, 2023
225.97 M Stocks
Jan 1, 2024
245.90 M Stocks
Jan 1, 2025
243.85 M Stocks
Jan 1, 2026 (e)
243.85 M Stocks
Jan 1, 2027 (e)
243.85 M Stocks
Jan 1, 2028 (e)
243.85 M Stocks

Current ADMA Biologics forecasts and price targets in August 2026

Analyst Price Targets 2026
Δ MOM Price Target
0.00 %
Buy
88.89 % (8)
Hold
11.11 % (1)
Sell
0.00 % (0)
12M Price Target
30.60
Last Price
9.96
Currency
USD
12M Return Potential
207.23 %
LTM Return
0 %

ADMA Biologics Analyst Rating Actions

DateFirmActionRatingReliability
7/15/2026
Mizuho
Mizuho
MaintainedOutperform31
5/7/2026
Mizuho
Mizuho
MaintainedOutperform31
5/7/2026
Canaccord Genuity
Canaccord Genuity
MaintainedBuy59
4/13/2026
Mizuho
Mizuho
MaintainedOutperform31
3/26/2026
Cantor Fitzgerald
Cantor Fitzgerald
DowngradeOverweightNeutral44
5/8/2025
Raymond James
Raymond James
MaintainedStrong Buy74
3/4/2025
Cantor Fitzgerald
Cantor Fitzgerald
MaintainedOverweight44
11/8/2024
Raymond James
Raymond James
MaintainedStrong Buy74
11/8/2024
HC Wainwright & Co.
HC Wainwright & Co.
MaintainedBuy–
10/14/2024
HC Wainwright & Co.
HC Wainwright & Co.
MaintainedBuy–

Eulerpool Reliability Score (0–100): measures how often a firm’s bullish or bearish calls were directionally correct three months later, blended with the average return following its calls. Every rating we record is stored permanently and scores update continuously; firms with fewer than 3 measured calls are not scored yet.

ADMA Biologics Earnings Calls

2025

ADMA Biologics Earnings Estimates & Surprises

DateEPS estimateEPS ActualRevenue EstimatePrice reactionQuarterly report
8/12/20260.18USD-134.29 MUSD-2026 Q2
5/13/20260.20USD-144.64 MUSD-2026 Q1
3/2/20260.19USD-142.19 MUSD-2025 Q4
11/6/20240.14USD-108.09 MUSD-2024 Q3
5/8/20240.03USD-73.21 MUSD-2024 Q1
3/21/20240.02USD-69.86 MUSD-2023 Q4
11/7/2023-0.05USD-50.58 MUSD-2023 Q3
8/8/2023-0.06USD-44.95 MUSD-2023 Q2
5/9/2023-0.06USD-41.45 MUSD-2023 Q1
3/22/2023-0.07USD-38.25 MUSD-2022 Q4

EESG©

Eulerpool ESG Scorecard© for the ADMA Biologics stock

33/100
34
Environment
46
Social
18
Governance
E

Environment

20
Scope 1 - Direct Emissions—
Scope 2 - Indirect emissions from purchased energy—
Scope 3 - Indirect emissions within the value chain—
Total CO₂ emissions—
CO₂ reduction strategy
Coal energy
Nuclear power
Animal experiments
Fur & Leather—
Pesticides—
Palm Oil—
Tobacco
Genetically modified organisms
Climate concept—
Sustainable forestry—
Recycling regulations
Environmentally friendly packaging
Hazardous substances
Fuel consumption and efficiency
Water consumption and efficiency
S

Social

20
Percentage of female employees—
Percentage of women in management—
Percentage of Asian employees—
Share of Asian management—
Percentage of Hispanic/Latino employees—
Hispano/Latino Management share—
Percentage of Black employees—
Black Management Share—
Percentage of white employees—
White Management Share—
Adult content
Alcohol
Weapons—
Firearms
Gambling
Military contracts
Human rights concept
Privacy concept—
Occupational health and safety
Catholic
G

Governance (Corporate Governance)

4
Environmental reporting
Stakeholder Engagement
Call Back Policies
Antitrust law

The Eulerpool ESG Scorecard© is the strictly copyrighted intellectual property of Eulerpool Research Systems. Any unauthorized use, imitation, or infringement will be actively pursued and may lead to significant legal consequences. For licenses, collaborations, or usage rights, please contact us directly via our contact form. Contact Form to us.

ADMA Biologics shareholder structure

% Name
15.03882%
BLACKROCK, INC.
BLACKROCK, INC.
13.62362%
BlackRock Institutional Trust Company, N.A.
BlackRock Institutional Trust Company, N.A.
8.49157%
The Vanguard Group, Inc.
The Vanguard Group, Inc.
5.75089%
STATE STREET CORP
STATE STREET CORP
5.55206%
State Street Investment Management (US)
State Street Investment Management (US)
4.64467%
Sachem Head Capital Management LP
Sachem Head Capital Management LP
...

ADMA Biologics Beneficial Ownership Filings (SEC 13D/G)

Free Float
97.8%
Float Shares
-
Shares Outstanding
-
StakeHolderFiling
25.00%
Biotest Pharmaceuticals Corporation
Biotest Pharmaceuticals Corporation
SEC ↗
25.00%
Biotest AG
Biotest AG
SEC ↗
21.80%
The Biotest Divestiture Trust
The Biotest Divestiture Trust
SEC ↗
21.80%
Eric Rosenbach
Eric Rosenbach
SEC ↗
19.40%
19.4%
19.4%
SEC ↗
19.40%
16,084,802
16,084,802
SEC ↗
15.10%
BlackRock, Inc.
BlackRock, Inc.
SEC ↗
14.10%
14.1%
14.1%
SEC ↗
14.10%
10
10
SEC ↗
11.00%
Timothy P. Lynch
Timothy P. Lynch
SEC ↗

ADMA Biologics Executives and Management Board

9 members · avg. age 58 · 22 % women

AG

Mr. Adam Grossman (48)

President, Chief Executive Officer, Co-Founder, Director · since 2007

7.92 M USD

Management

KK

Ms. Kaitlin Kestenberg (38)

Chief Operating Officer, Senior Vice President - Compliance

3.34 M USD
TK

Mr. Terry Kohler (48)

Chief Financial Officer, Treasurer

–

Board of Directors

SE

Mr. Steven Elms (61)

Independent Chairman of the Board

351,176.00 USD
JG

Dr. Jerrold Grossman (77)

Vice Chairman of the Board, Co-Founder

344,399.00 USD
LG

Mr. Lawrence Guiheen (74)

Independent Director

334,774.00 USD
YK

Dr. Young Kwon (53)

Independent Director

333,240.00 USD
AF

Ms. Alison Finger (61)

Independent Director

305,977.00 USD
ES

Mr. Eduardo Salas (63)

Independent Director

214,537.00 USD

ADMA Biologics Supply Chain

ADMA Biologics Supply Chain

Correlation: how closely stock prices move together

Same directionNo relationOpposite
2 companies
#Nameβ 1YTrend
1
Grifols A
Supplier·Biotechnology·ES
0.30
-0.07
0.48
-0.01
-0.19
0.60
-0.15
2
Takeda Pharmaceutical
Customer·Pharmaceuticals·JP
0.67
-0.25
0.65
0.88
0.35
0.57
0.19

Frequently asked questions about ADMA Biologics

ADMA Biologics Inc operates as a biopharmaceutical company. The company develops and produces specialty plasma-derived products for the treatment of immune deficiencies and infectious diseases. ADMA Biologics focuses on the production and marketing of its hyperimmune globulin products, which are used to treat various medical conditions. With its emphasis on specialty plasma-derived products, ADMA Biologics Inc aims to improve patient outcomes and address unmet medical needs.

ADMA Biologics Inc is primarily active in the biopharmaceutical and healthcare industries.

The main competitors of ADMA Biologics Inc in the market include companies such as Grifols, CSL Ltd, and Octapharma.

ADMA Biologics Inc is a biopharmaceutical company specializing in the development and commercialization of plasma-derived products for the treatment of immune deficiencies and other infectious diseases. Founded in 2004, ADMA Biologics has evolved into a leading player in the immunoglobulin market. The company operates its own plasma collection centers and has a state-of-the-art fractionation facility located in Boca Raton, Florida. ADMA Biologics strives to deliver high-quality, plasma-derived products to patients with unmet medical needs. With a strong commitment to innovation and excellence, ADMA Biologics continues to expand its product pipeline and market presence, aiming to improve the lives of patients worldwide. Note: The provided answer is only for reference purposes and should be tailored or reviewed according to the specific requirements or guidelines provided by the professional stock website.

ADMA Biologics Inc has achieved significant milestones in its journey. The company has successfully gained FDA approval for its first plasma-derived biologic, RI-002™. In addition, they have expanded their product portfolio by launching BIVIGAM®, a treatment for primary humoral immunodeficiency, and ASCENIV™, a hyperimmune globulin. ADMA Biologics Inc also received FDA approval for acquisition of their BOC facility in Boca Raton, Florida, which has resulted in increased plasma collection capacity. These milestones have strengthened ADMA Biologics Inc's position in the market and reflect their commitment to providing innovative solutions and expanding their reach in the biopharmaceutical industry.

ADMA Biologics Inc is primarily present in the United States.

ADMA Biologics Inc represents a strong commitment to developing and delivering innovative plasma-derived products for the treatment of immune deficiencies and other infectious diseases. The company's corporate philosophy centers around maximizing patient access to life-saving therapies, ensuring product quality and safety, and fostering a culture of excellence in research and development. ADMA Biologics Inc values integrity, collaboration, and dedication to improving patient outcomes. Through its cutting-edge technologies and strategic partnerships, the company strives to address unmet medical needs and make a positive impact on global healthcare. ADMA Biologics Inc is dedicated to providing high-quality products and delivering value to patients, healthcare professionals, and stakeholders.

Analysts currently set an average price target of 26.18 USD for the ADMA Biologics stock (median: 30.60 USD), implying +162.9 % versus the latest price. The consensus is based on 9 analyst ratings.

ADMA Biologics Analyst Price Targets 2026

9 analysts currently rate the ADMA Biologics stock: 8 recommend buying, 1 holding and 0 selling. For 2026, analysts expect ADMA Biologics to generate revenue of 535.35 M USD and earnings per share of 0.80 USD.

ADMA Biologics Analyst Price Targets 2026

Converted at the current exchange rate, the ADMA Biologics share trades at 8.61 EUR (9.96 USD).

The ADMA Biologics share (ADMA) is listed on 1 stock exchanges, including: NASDAQ (ADMA).

ADMA Biologics Inc is a US biopharmaceutical company focused on the development of intravenous immunoglobulins (IVIG). The company was founded in 2004 and is headquartered in Ramsey, New Jersey. ADMA Biologics Inc's business model is based on the production and marketing of IVIG products for the treatment of primary immune deficiency diseases (PID). The company is divided into three business segments: manufacturing, sales and marketing of IVIG products, pipeline product development, and management of licenses and patents. ADMA Biologics Inc currently produces two IVIG products: BIVIGAM and ASCENIV. BIVIGAM is used to treat primary immune deficiency diseases, while ASCENIV is administered through intravenous push-injection. ADMA Biologics Inc is also working on developing additional IVIG products, and holds licenses and patents in the field of plasma proteins and related technologies. In summary, ADMA Biologics Inc's business model revolves around the production and marketing of IVIG products for the treatment of primary immune deficiency diseases. The company is involved in manufacturing, sales, and marketing of these products, as well as the development of new pipeline products. They also hold licenses and patents in the field of plasma proteins and related technologies.

The expected revenue of ADMA Biologics is 535.35 M USD. This figure is based on current financial data and reflects the company's business performance.

The expected profit of ADMA Biologics is 195.12 M USD. The net profit reflects the company's profitability after deducting all expenses.

The price-to-earnings ratio (P/E) of ADMA Biologics is currently 12.45. The P/E ratio compares the current share price to the earnings per share and helps investors assess the valuation of the ADMA Biologics stock.

The price-to-sales ratio (P/S) of ADMA Biologics is currently 4.54. The P/S ratio compares the market capitalization to the annual revenue and serves as a valuation metric for the ADMA Biologics stock.

The Eulerpool Quality Score for ADMA Biologics is 7/10.

The ISIN of ADMA Biologics is US0008991046. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.

The WKN of ADMA Biologics is A12FAG. The WKN (Wertpapierkennnummer) is a six-digit German security identification number.

The ticker of ADMA Biologics is ADMA. The ticker symbol is used to trade ADMA Biologics shares on the stock exchange.

ADMA Biologics paid dividends every year for the past 0 years.

ADMA Biologics is assigned to the 'Health' sector.

The dividends of ADMA Biologics are distributed in USD.

All fundamentals and in-depth analysis of ADMA Biologics

Our stock analysis for ADMA Biologics stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of ADMA Biologics. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.

ADMA Biologics Stock
ADMA Biologics Revenue→
ADMA Biologics Stock
ADMA Biologics Net Income→
ADMA Biologics Stock
ADMA Biologics P/E→
ADMA Biologics Stock
ADMA Biologics P/S→
ADMA Biologics Stock
ADMA Biologics EBIT→
ADMA Biologics Stock
ADMA Biologics Dividend→
ADMA Biologics Stock
ADMA Biologics Directors Dealings→
ADMA Biologics Stock
ADMA Biologics Stocks→
ADMA Biologics Stock
ADMA Biologics Market capitalization→
ADMA Biologics Stock
ADMA Biologics Debt→
ADMA Biologics Stock
ADMA Biologics Liabilities→
ADMA Biologics Stock
ADMA Biologics Equity→
ADMA Biologics Stock
ADMA Biologics AAQS→
ADMA Biologics Stock
ADMA Biologics Employees→
ADMA Biologics Stock
ADMA Biologics ROE→
ADMA Biologics Stock
ADMA Biologics ROA→
ADMA Biologics Stock
ADMA Biologics ROCE→
ADMA Biologics Stock
ADMA Biologics News→
ADMA Biologics Stock
ADMA Biologics Analyst Price Targets→

Health Stocks

AdociaAdlai Nortye Ltd. American Depositary SharesAdvagene Biopharma CoAditxtAdvanced BiomedAdimmuneAdvanced Biomedical TechnologiesAdicon HoldingsAdvanced Medical Solutions GroupAdicet BioAdvanced Technology Co KSCPAdial PharmaceuticalsAll Stocks A–Z →